Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Personalized Medicine Biomarkers Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The personalized medicine biomarkers market size has experienced rapid growth in recent years. It is projected to expand from $26.73 billion in 2025 to $31.34 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.3%. This historical growth can be attributed to advancements in genomic research, an increasing incidence of cancer, the proliferation of targeted therapies, wider application of molecular diagnostics, and supportive regulatory frameworks for precision medicine.
The personalized medicine biomarkers market size is anticipated to experience rapid growth in the upcoming years. It is projected to reach $58.8 billion by 2030, at a compound annual growth rate (CAGR) of 17.0%. This growth during the forecast period is attributed to the expansion of personalized therapeutics, a rising demand for early disease detection, growth in pharmacogenomics, increasing investment in biomarker discovery, and wider adoption across non-oncology indications. Key trends for the forecast period encompass the rising adoption of precision treatment approaches, increasing use of biomarkers in oncology care, growing integration of companion diagnostics, the expansion of predictive and prognostic biomarkers, and a higher focus on treatment response monitoring.
Get A Free Sample Report With In-Depth Market Insights:
Personalized Medicine Biomarkers Market Growth Drivers: What’s Behind The Acceleration?
The increasing occurrence of chronic illnesses is anticipated to boost the expansion of the personalized medicine biomarkers market in the future. Chronic illnesses are enduring health issues characterized by gradual development, lasting a minimum of one year, and necessitating continuous medical care or restricting everyday functions. This rising prevalence of chronic conditions stems from factors such as unhealthy lifestyle choices, poor nutritional habits, insufficient physical exercise, and elevated stress levels. Personalized medicine biomarkers aid in customizing treatments for chronic ailments by pinpointing efficacious therapies, forecasting disease advancement, and reducing negative reactions, all informed by a person’s unique genetic and molecular characteristics. For example, data released in February 2024 by the World Health Organization (WHO), a health authority based in Switzerland, projects that by 2050, new cancer cases will exceed 35 million, which signifies a 77% surge from the approximate 20 million cases recorded in 2022. Consequently, the increasing incidence of chronic diseases is propelling the expansion of the personalized medicine biomarkers market.
Personalized Medicine Biomarkers Market Segment Analysis And Revenue Potential
The personalized medicine biomarkers market covered in this report is segmented –
1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types
2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications
3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring
4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users
Subsegments:
1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers
2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers
3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers
4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers
Personalized Medicine Biomarkers Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies within the personalized medicine biomarkers market are concentrating on securing regulatory authorizations, including companion diagnostic approval, to improve precision oncology by quickly connecting patients with specific therapies. Companion diagnostic approval denotes the official permission granted by a health authority, such as the FDA, for a diagnostic test specifically engineered to identify individuals who would most likely benefit from a certain therapeutic product or face a greater risk of adverse reactions. As an illustration, in August 2024, Illumina, Inc., a US-based biotechnology company, obtained Food and Drug Administration (FDA) approval for its cancer biomarker test and two companion diagnostics. The test employs next-generation sequencing (NGS) technology to find genetic mutations in cancer cells, allowing clinicians to select the most appropriate treatments based on individual biomarkers. This approval signifies a major step forward in precision oncology, intending to enhance the speed and precision of treatment selection for cancer patients, thereby elevating personalized care.
Personalized Medicine Biomarkers Market Key Players Shaping Industry Direction
Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.
View The Full Personalized Medicine Biomarkers Market Report:
Personalized Medicine Biomarkers Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model